Ignite Creation Date:
2025-12-24 @ 2:56 PM
Ignite Modification Date:
2026-01-01 @ 7:19 PM
Study NCT ID:
NCT01277159
Status:
COMPLETED
Last Update Posted:
2022-04-14
First Post:
2011-01-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000377', 'term': 'Agnosia'}], 'ancestors': [{'id': 'D010468', 'term': 'Perceptual Disorders'}, {'id': 'D019954', 'term': 'Neurobehavioral Manifestations'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D003907', 'term': 'Dexamethasone'}, {'id': 'D012965', 'term': 'Sodium Chloride'}, {'id': 'D002047', 'term': 'Buprenorphine'}], 'ancestors': [{'id': 'D011246', 'term': 'Pregnadienetriols'}, {'id': 'D011245', 'term': 'Pregnadienes'}, {'id': 'D011278', 'term': 'Pregnanes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D013259', 'term': 'Steroids, Fluorinated'}, {'id': 'D002712', 'term': 'Chlorides'}, {'id': 'D006851', 'term': 'Hydrochloric Acid'}, {'id': 'D017606', 'term': 'Chlorine Compounds'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017670', 'term': 'Sodium Compounds'}, {'id': 'D009019', 'term': 'Morphinans'}, {'id': 'D053610', 'term': 'Opiate Alkaloids'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D006572', 'term': 'Heterocyclic Compounds, Bridged-Ring'}, {'id': 'D006576', 'term': 'Heterocyclic Compounds, 4 or More Rings'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D010616', 'term': 'Phenanthrenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'YadeauJ@hss.edu', 'phone': '212.606.1206', 'title': 'Dr. Yadeau', 'organization': 'HSS'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'Control Nerve Block. IV Dexamethasone (4 mg).', 'description': 'Control Nerve Block. IV Dexamethasone (4 mg).\n\nA. Control Nerve Block. IV Dexamethasone (4 mg).: A. Control Nerve Block. IV Dexamethasone (4 mg).', 'otherNumAtRisk': 17, 'otherNumAffected': 0, 'seriousNumAtRisk': 17, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Nerve Block With Dexamethasone (4 mg). IV Saline.', 'description': 'B. Nerve Block with Dexamethasone (4 mg). IV saline.\n\nB. Nerve Block with Dexamethasone (4 mg). IV saline.: B. Nerve Block with Dexamethasone (4 mg). IV saline.', 'otherNumAtRisk': 21, 'otherNumAffected': 0, 'seriousNumAtRisk': 21, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp', 'description': 'Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)\n\nC. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg): C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)', 'otherNumAtRisk': 19, 'otherNumAffected': 0, 'seriousNumAtRisk': 19, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Nerve Block With Buprenorphine (0.3 mg). IV Dexamethasone (', 'description': 'Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).\n\nD. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).', 'otherNumAtRisk': 19, 'otherNumAffected': 0, 'seriousNumAtRisk': 19, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Nerve Block With Dexamethasone (4 mg) / Block Buprenorphine', 'description': 'Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.\n\nE. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).\n\nIV saline.', 'otherNumAtRisk': 16, 'otherNumAffected': 0, 'seriousNumAtRisk': 16, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Time it Takes for Nerve Block to Wear Off', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}, {'value': '16', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Control Nerve Block. IV Dexamethasone (4 mg).', 'description': 'Control Nerve Block. IV Dexamethasone (4 mg).\n\nA. Control Nerve Block. IV Dexamethasone (4 mg).: A. Control Nerve Block. IV Dexamethasone (4 mg).'}, {'id': 'OG001', 'title': 'Nerve Block With Dexamethasone (4 mg). IV Saline.', 'description': 'B. Nerve Block with Dexamethasone (4 mg). IV saline.\n\nB. Nerve Block with Dexamethasone (4 mg). IV saline.: B. Nerve Block with Dexamethasone (4 mg). IV saline.'}, {'id': 'OG002', 'title': 'Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp', 'description': 'Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)\n\nC. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg): C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)'}, {'id': 'OG003', 'title': 'Nerve Block With Buprenorphine (0.3 mg). IV Dexamethasone (', 'description': 'Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).\n\nD. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).'}, {'id': 'OG004', 'title': 'Nerve Block With Dexamethasone (4 mg) / Block Buprenorphine', 'description': 'Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.\n\nE. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).\n\nIV saline.'}], 'classes': [{'categories': [{'measurements': [{'value': '30.4', 'spread': '5.1', 'groupId': 'OG000'}, {'value': '45.1', 'spread': '5.2', 'groupId': 'OG001'}, {'value': '32.2', 'spread': '6.1', 'groupId': 'OG002'}, {'value': '45.6', 'spread': '5.6', 'groupId': 'OG003'}, {'value': '45.6', 'spread': '5.8', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'up to 72 hours', 'description': 'Does adding dexamethasone and / or buprenorphine prolong the analgesia provided by a popliteal fossa nerve block?', 'unitOfMeasure': 'hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Control Nerve Block. IV Dexamethasone (4 mg).', 'description': 'Control Nerve Block. IV Dexamethasone (4 mg).\n\nA. Control Nerve Block. IV Dexamethasone (4 mg).: A. Control Nerve Block. IV Dexamethasone (4 mg).'}, {'id': 'FG001', 'title': 'Nerve Block With Dexamethasone (4 mg). IV Saline.', 'description': 'B. Nerve Block with Dexamethasone (4 mg). IV saline.\n\nB. Nerve Block with Dexamethasone (4 mg). IV saline.: B. Nerve Block with Dexamethasone (4 mg). IV saline.'}, {'id': 'FG002', 'title': 'Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp', 'description': 'Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)\n\nC. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg): C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)'}, {'id': 'FG003', 'title': 'Nerve Block With Buprenorphine (0.3 mg). IV Dexamethasone (', 'description': 'Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).\n\nD. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).'}, {'id': 'FG004', 'title': 'Nerve Block With Dexamethasone (4 mg) / Block Buprenorphine', 'description': 'Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.\n\nE. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).\n\nIV saline.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '21'}, {'groupId': 'FG001', 'numSubjects': '22'}, {'groupId': 'FG002', 'numSubjects': '22'}, {'groupId': 'FG003', 'numSubjects': '22'}, {'groupId': 'FG004', 'numSubjects': '21'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '17'}, {'groupId': 'FG001', 'numSubjects': '21'}, {'groupId': 'FG002', 'numSubjects': '19'}, {'groupId': 'FG003', 'numSubjects': '19'}, {'groupId': 'FG004', 'numSubjects': '16'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '5'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '19', 'groupId': 'BG002'}, {'value': '19', 'groupId': 'BG003'}, {'value': '16', 'groupId': 'BG004'}, {'value': '92', 'groupId': 'BG005'}]}], 'groups': [{'id': 'BG000', 'title': 'Control Nerve Block. IV Dexamethasone (4 mg).', 'description': 'Control Nerve Block. IV Dexamethasone (4 mg).\n\nA. Control Nerve Block. IV Dexamethasone (4 mg).: A. Control Nerve Block. IV Dexamethasone (4 mg).'}, {'id': 'BG001', 'title': 'Nerve Block With Dexamethasone (4 mg). IV Saline.', 'description': 'B. Nerve Block with Dexamethasone (4 mg). IV saline.\n\nB. Nerve Block with Dexamethasone (4 mg). IV saline.: B. Nerve Block with Dexamethasone (4 mg). IV saline.'}, {'id': 'BG002', 'title': 'Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp', 'description': 'Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)\n\nC. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg): C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)'}, {'id': 'BG003', 'title': 'Nerve Block With Buprenorphine (0.3 mg). IV Dexamethasone (', 'description': 'Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).\n\nD. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).'}, {'id': 'BG004', 'title': 'Nerve Block With Dexamethasone (4 mg) / Block Buprenorphine', 'description': 'Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.\n\nE. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).\n\nIV saline.'}, {'id': 'BG005', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '19', 'groupId': 'BG002'}, {'value': '19', 'groupId': 'BG003'}, {'value': '16', 'groupId': 'BG004'}, {'value': '92', 'groupId': 'BG005'}]}], 'categories': [{'measurements': [{'value': '51.29', 'spread': '6.8', 'groupId': 'BG000'}, {'value': '47.81', 'spread': '9.5', 'groupId': 'BG001'}, {'value': '46.26', 'spread': '7.5', 'groupId': 'BG002'}, {'value': '47.95', 'spread': '8.6', 'groupId': 'BG003'}, {'value': '52.19', 'spread': '7.2', 'groupId': 'BG004'}, {'value': '49.1', 'spread': '8.6', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '19', 'groupId': 'BG002'}, {'value': '19', 'groupId': 'BG003'}, {'value': '16', 'groupId': 'BG004'}, {'value': '92', 'groupId': 'BG005'}]}], 'categories': [{'title': 'Female', 'measurements': [{'value': '11', 'groupId': 'BG000'}, {'value': '13', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}, {'value': '14', 'groupId': 'BG003'}, {'value': '13', 'groupId': 'BG004'}, {'value': '61', 'groupId': 'BG005'}]}, {'title': 'Male', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '31', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race and Ethnicity Not Collected', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'populationDescription': 'Race and Ethnicity were not collected from any participant.'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 108}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2010-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-04', 'completionDateStruct': {'date': '2011-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-04-12', 'studyFirstSubmitDate': '2011-01-13', 'resultsFirstSubmitDate': '2017-03-27', 'studyFirstSubmitQcDate': '2011-01-13', 'lastUpdatePostDateStruct': {'date': '2022-04-14', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2017-08-01', 'studyFirstPostDateStruct': {'date': '2011-01-14', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2017-08-31', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2011-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Time it Takes for Nerve Block to Wear Off', 'timeFrame': 'up to 72 hours', 'description': 'Does adding dexamethasone and / or buprenorphine prolong the analgesia provided by a popliteal fossa nerve block?'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Analgesia', 'Duration', 'Popliteal Fossa Nerve Block', 'Dexamethasone', 'Buprenorphine', 'Additives', 'Ankle surgery'], 'conditions': ['Patients Undergoing Ankle Surgery']}, 'descriptionModule': {'briefSummary': 'Patients scheduled to go home after ankle surgery at HSS typically receive a sciatic nerve block in the popliteal fossa and oral analgesic tablets (such as Percocet). Popliteal fossa nerve blockade has reduced pain for these patients (YaDeau et al, Anesth Analg 2008;106:1916-20), but unfortunately the patients still often experience moderate to severe pain after the block wears off. The investigators wish to study two additives that may prolong the period of analgesia provided by the nerve block. The additives will be studied in the context of a standardized postoperative multimodal analgesic pathway.\n\nPrimary outcome:\n\nDoes adding dexamethasone and / or buprenorphine prolong the analgesia provided by a popliteal fossa nerve block?'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Patients of Dr Levine or Dr Roberts.\n2. Scheduled for discharge from HSS after foot or ankle surgery.\n3. A single-injection popliteal fossa nerve block is judged appropriate.\n4. Surgery confined to foot and ankle (no iliac crest bone graft planned - iliac aspirate is not an exclusion criterion).\n5. Patients aged 18-75 years.\n\nExclusion Criteria:\n\n* Surgery that will cause pain at sites outside the distal lower extremity (e.g. iliac crest bone graft).\n* Bilateral surgery\n* Chronic pain (defined as regular use of opioid analgesics for \\> 3 months).\n* Chronic use of steroids (defined as regular use of steroids for \\> 3 months).\n* Contraindication to performance of the popliteal fossa nerve block with 30 cc 0.25% bupivacaine with clonidine (e.g. alleged bupivacaine sensitivity, low body weight, clonidine allergy, etc.).\n* Contraindications to dexamethasone or buprenorphine (e.g. allergy, Insulin Dependent Diabetes Mellitus, etc.)\n* Inability of the patient to describe postoperative pain (e.g. psychiatric disorder, dementia).\n* Non-English speaking patients (the questionnaire is in English, and translations would have to be separately validated)'}, 'identificationModule': {'nctId': 'NCT01277159', 'briefTitle': 'Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine', 'organization': {'class': 'OTHER', 'fullName': 'Hospital for Special Surgery, New York'}, 'officialTitle': 'Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine', 'orgStudyIdInfo': {'id': '2012-042'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Control Nerve Block. IV Dexamethasone (4 mg).', 'description': 'Control Nerve Block. IV Dexamethasone (4 mg).', 'interventionNames': ['Drug: A. Control Nerve Block. IV Dexamethasone (4 mg).']}, {'type': 'EXPERIMENTAL', 'label': 'Nerve Block with Dexamethasone (4 mg). IV saline.', 'description': 'B. Nerve Block with Dexamethasone (4 mg). IV saline.', 'interventionNames': ['Drug: B. Nerve Block with Dexamethasone (4 mg). IV saline.']}, {'type': 'EXPERIMENTAL', 'label': 'Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp', 'description': 'Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)', 'interventionNames': ['Drug: C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)']}, {'type': 'EXPERIMENTAL', 'label': 'Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (', 'description': 'Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).', 'interventionNames': ['Drug: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).']}, {'type': 'EXPERIMENTAL', 'label': 'Nerve Block with Dexamethasone (4 mg) / block Buprenorphine', 'description': 'Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.', 'interventionNames': ['Drug: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).']}], 'interventions': [{'name': 'A. Control Nerve Block. IV Dexamethasone (4 mg).', 'type': 'DRUG', 'description': 'A. Control Nerve Block. IV Dexamethasone (4 mg).', 'armGroupLabels': ['Control Nerve Block. IV Dexamethasone (4 mg).']}, {'name': 'B. Nerve Block with Dexamethasone (4 mg). IV saline.', 'type': 'DRUG', 'description': 'B. Nerve Block with Dexamethasone (4 mg). IV saline.', 'armGroupLabels': ['Nerve Block with Dexamethasone (4 mg). IV saline.']}, {'name': 'C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)', 'type': 'DRUG', 'description': 'C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)', 'armGroupLabels': ['Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp']}, {'name': 'D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).', 'type': 'DRUG', 'description': 'D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).', 'armGroupLabels': ['Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (']}, {'name': 'E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).', 'type': 'DRUG', 'description': 'E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.', 'armGroupLabels': ['Nerve Block with Dexamethasone (4 mg) / block Buprenorphine']}]}, 'contactsLocationsModule': {'locations': [{'zip': '10021', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Hospital for Special Surgery', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}], 'overallOfficials': [{'name': 'Michael Urban', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital for Special Surgery, New York'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hospital for Special Surgery, New York', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}